BRCA2 and myasthenia gravis: While there are remarkable differences between the surveyed guideline in the screening recommendations regarding MG use (Table 2), at this stage, only NABON guidelines distinguish between the recommended imaging surveillance scheme for BRCA1 and BRCA2 P/LPV carriers [68], while the American College of Radiology (ACR), Austrian Clinical Practice Guideline, and SEOM guidelines suggest considering/discussing delaying MG until age 40 years for BRCA1 P/LPV carriers undergoing annual MRI screening [25,66,69].